Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011

Last updated: March 23, 2026
Sponsor: IDBiologics, Inc.
Overall Status: Active - Not Recruiting

Phase

1

Condition

Fungal Infections

Systemic Fungal Infections

Treatment

Placebo

IDB-011 dose level 3

IDB-011 dose level 5

Clinical Study ID

NCT06925919
IDB-RVFV-101
  • Ages 18-64
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy adult participants.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy male or female

  • Body mass index (BMI) within 18.0 kg/m2 to 30.0 kg/m^2, inclusively

  • Female participants must not be pregnant, breastfeeding or intend to become pregnantthrough 1 year post-administration

  • Male subjects must agree to not cause pregnancy or donate sperm for 1 yearpost-administration

  • Non-smoker

  • Agree to abstain from alcohol for 72 hours and caffeine for 48 hours prior toadministration and during the confinement period

  • Agree to not donate blood or plasma during study participation

  • Agree not to travel to Rift Valley fever virus (RVFV) endemic areas duringparticipation

Exclusion

Exclusion Criteria:

  • Known history of RVFV infection

  • Previous receipt of RVFV vaccine

  • Illness with fever within 5 days prior to administration

  • History of malignancy within prior 5 years

  • History of significant cardiovascular, pulmonary, gastrointestinal, liver, kidney,hematologic, neurological, psychiatric, endocrine, immunologic, dermatologic disease

  • History of hypersensitivity reaction

  • History or clinical evidence of alcohol abuse

  • Human immunodeficiency virus (HIV) positive

  • Hepatitis C virus positive

  • Hepatitis B virus positive

  • Received immunoglobulin or antibody product within 6 months of administration

  • Vaccine within 28 days of administration

  • Received investigational agent within 3 months or < 5 half-lives (whichever islonger) prior to administration

  • Donation of plasma, 1 unit or > 500 mL blood donation in 56 days prior toadministration

Study Design

Total Participants: 40
Treatment Group(s): 6
Primary Treatment: Placebo
Phase: 1
Study Start date:
April 02, 2025
Estimated Completion Date:
October 31, 2026

Study Description

This is a randomized, double blind, placebo-controlled, dose escalation, first-in-human, Phase I clinical trial to assess the safety, tolerability, PK and immunogenicity of IDB-011 in healthy volunteers aged 18-64. IDB-011 is comprised of IDB-774 and IDB-898, which will be administered as separate, consecutive intramuscular injections.

Volunteers will be recruited into sequential dosing cohorts. Within each cohort, eligible volunteers will be randomly allocated (6:2) to receive either IDB-011 or placebo (0.9% normal saline). A sentinel dosing scheme will be employed for the first 2 volunteers in each dosing cohort.

Volunteers will stay in a clinical research unit for up to 4 consecutive days and be followed for up to 1 year.

Connect with a study center

  • Altasciences Clinical Los Angeles

    Cypress, California 90630
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.